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Abstract Opsoclonus-myoclonus syndrome (OMS) in chil-
dren is a rare neurological condition with opsoclonus,
myoclonus, ataxia and irritability in the first 2 years of life.
It can be idiopathic, parainfectious, or paraneoplastic with
tumours of the neural crest. Few studies of long-term
follow-up after OMS have been published. We investigated
the motor, cognitive and behavioural outcome of ten
patients (eight girls and two boys) seen between 1987 and
2002. We reviewed the records and reassessed the patients.
A ganglioneuroma was found in one patient and a
neuroblastoma in another. Tumour resection did not
influence the OMS. The age at diagnosis was 10–24 months
and the follow-up period 1–17 years (average 6.5 years).
The interval between the first signs and symptoms and
starting treatment was 2–12 weeks: treatment consisted of
different immunosupressants. Remission was achieved
within 5 months in seven, and relapses were present in
seven of ten. At follow-up, only one child had mild ataxia.
IQ testing was performed in nine with scores below 75 in
four and above 85 in four. Attention deficit and visuomotor
difficulties led to school problems with special needs, also
in those three children with normal IQs. Only two children
were attending regular schools. Behavioural problems were
reported in seven, and speech difficulties were present in
five. In conclusion, the long-term outcome in our patients
with OMS was dominated by cognitive and behavioural
problems and not by ataxia. Compared with previous
reports, our patients were treated earlier. Larger studies
and uniform treatment protocols are needed to demonstrate
whether early and prolonged immunosupressant therapy has
a favourable influence on outcome.
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Introduction
Opsoclonus-myoclonus syndrome (OMS) in childhood is a
rare neurological condition with an acute onset of myoclo-
nus, opsoclonus, and ataxia. Opsoclonus is defined as
repetitive involuntary, irregular, rapid conjugate eye move-
ments, often precipitated by saccades. Myoclonia are
multifocal small-amplitude muscle jerks frequently accom-
panied by cerebellar ataxia. There is a rapid loss of motor
control and speech, and regression from developmental
milestones. The children are highly irritable and already
have severe sleep disturbances in the prodromal phase [17].
In contrast to OMS, acute post-infectious cerebellar ataxia
is never accompanied by either myoclonia or opsoclonus
and rarely by irritability. OMS usually occurs in the first
2 years of life and is associated with viral infections or
tumours of the neural crest. Only about 2–3% of patients
with neuroblastoma have paraneoplastic OMS, and their
survival is substantially longer than in children with
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neuroblastoma without OMS [22]. Neuroblastoma in the
presence of OMS is usually low stage with favourable
histology, normal catecholamine excretion, and a single
copy of the n-myc oncogene.
The aetiology of OMS is still debated. There is strong
evidence for it being an antibody-mediated disease, but so
far no specific autoantibody has been found [2, 3, 9, 20].
Reported treatment options include oral corticosteroids,
high-dose methylprednisolone, corticotropin (ACTH), in-
travenous immunoglobulin, cyclophosphamide and plasma-
pheresis. Recently, Pranzatelli et al. reported a good
response to rituximab [19].
The long-term neurological outcome in patients with
OMS has been studied in patients with associated neuro-
blastoma [7, 8, 13, 15]. There are also studies of mixed
populations, including patients with OMS of paraneoplastic
or parainfectious origin [6, 12, 14, 16, 24]. The reports of
long-term outcome include descriptions of persistent and
disabling ataxia, speech abnormalities, behavioural prob-
lems, and learning disabilities of differing severity and
frequency. No correlation between the outcome and the
response to therapy or removal of the tumour has yet been
found [7, 13, 15, 16, 24]. A recent longitudinal study
showed a correlation between the outcome and course of
the disease, with a worse outcome in patients with multiple
relapses [12].
We were interested in the long-term outcome in our
patients, focussing particularly on motor, cognitive and
behavioural problems.
Patients and methods
The medical records of patients with OMS seen between
1987 and 2002 were reviewed and the patients reassessed
by interview and neurological examination. Nine of ten had
additional neurospychological testing.
Ataxia and dysmetria were graded as severe, moderate,
mild or minimal according to the degree of the disturbance
of activities of daily living: severe: unable to walk
unassisted; moderate: wide-based gait, frequent falls, and
overt dysmetria; mild: infrequent falls, gross motor prob-
lems, and fine motor difficulties in drawing or writing;
minimal: no gait ataxia or dysmetria on neurological
examination, but the children were outside the age-specific
normal range in the pegboard and equilibrium subtest of the
Zurich Neuromotor Assessment [10].
When possible, developmental status and cognitive
function were tested according to age with SON-R [25],
HAWIVA [5] or HAWIK-III [26].
Behavioural problems were assessed by parent interview
and with the Child Behavior Checklist (CBCL) [1, 4].
Results
Between 1987 and 2003, ten patients (eight girls and two
boys) with OMS were seen. A retroperitoneal neuroblasto-
ma was diagnosed in one patient, and a retroperitoneal
ganglioneuroma in another. The age at diagnosis was 10–
24 months (mean, 18 months). During the acute stage, all
patients showed opsoclonus, myoclonus and ataxia; eight
patients were unable to sit, and two were able to walk with
assistance. All were highly irritable and had disturbed
sleep. Two lost speech for several weeks.
Therapy was started 2–12 weeks (median, 3 weeks) after
the onset of symptoms; oral prednisolone was the first step
in all patients. Intravenous immunoglobulin (IVIG) was
given subsequently in six patients because of symptom
relapses or prednisolone dependence. Two were treated
with high-dose methylprednisolone (3 days of 30 mg/kg/day
and 50 mg/kg/day, respectively) and IVIG (six to eight
cycles at 4–8-week intervals) with good effect. One patient
was treated with cyclophosphamide and three with azathi-
oprine. In two patients, cyclosporin A had a good effect on
opsoclonus and myoclonus with persisting ataxia, and in one
patient a relapse with ataxia and opsoclonus responded to
cyclosporin A. A first remission of opsoclonus and
myoclonus under immunosupressant medication was
achieved in less than 5 months in seven patients. Relapses,
defined by worsening of ataxia, opsoclonus and myoclonus
after first remission, were present in four of seven. In the
remaining three patients, symptoms were only partially
controlled over 12–24 months, and they also suffered
relapses (Table 1). Two patients were still being treated
with cyclosporin A at the time of re-evaluation.
Re-evaluation (see also Table 1)
The interval between the onset of OMS and re-evaluation
was 1–17 years (mean 6.5 years). The age at reassessment
was 3 to 17.7 years.
Ataxia
Five of ten had no ataxia and were age appropriate in the
pegboard and equilibrium test of the Zurich Neuromotor
Assessment test. Four of ten were graded as having
minimal ataxia; they had no gait ataxia and no difficulties
in everyday life, but were not age appropriate in the
equilibrium test. Only one 5-year-old girl had mild gait
ataxia.
Dysmetria
Five of ten were within the normal range of the age-specific
norms for the pegboard test. Five of ten did not reach this
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range, but only the girl with mild gait ataxia had difficulties
in daily living because of fine motor problems.
Speech
Four of ten had a hoarse voice; expressive speech
abnormalities such as a slightly slurred speech, articulation
problems or word-finding difficulties were present in five
of ten; three were difficult to understand, and one had
needed speech therapy earlier.
Cognitive performance
Nine patients were tested. The IQ was >85 in four of eight,
in one patient it was between 75 and 85, and four of eight
had an IQ <75. A 3-year-old child was not tested, but was
age appropriate clinically.
School performance
Two children were not yet of school age. Although four of
eight had a normal IQ, only two were able to attend regular
school: four of ten needed special education for learning
disabled children, and two attended a special class of longer
duration with fewer pupils, but with regular academic aims.
Behaviour
In the interview, eight of ten children were described by the
parents as more difficult than their siblings or peers.
Mainly, they were impulsive, aggressive and emotionally
unstable. In the Child Behavior Checklist (Achenbach
CBCL), two children had normal results (normative mean
50, SD 10), five of ten had borderline scores between 60
and 63, and two had T scores >63; one scored 73, which is
considered to be clinically significant problematic behav-
iour, with externalising symptoms predominating. In two
children the CBLC questionnaire was not applicable
because of their age, but they were described as easy
children by the parents. In the subtests, five of ten had signs
of attention problems.
Neuroimaging
A cerebral MRI was performed in two children, 8 and
16 years after the acute stage, demonstrating moderate and
mild atrophy of the cerebellar hemispheres and vermis,
respectively. At the time of the investigation both children
had only mild ataxia; the girl with moderate atrophy had an
IQ <50 whilst the boy attended regular school.
Discussion
The long-term neurological outcome of patients with OMS
has been studied in patients with associated neuroblastoma
[7, 8, 13, 15] and in mixed populations of patients with
OMS of paraneoplastic, “idiopathic” or parainfectious
origin [6, 14, 16, 24]. In these reports, paraneoplastic
OMS was seen in 7–90% of the patients. In studies with US
patients [6, 24], 41–90% were reported to have paraneo-
plastic OMS compared with 7% in a larger European study
Table 1 Summary of neurological and neuropsychological outcome at re-evaluation
Age at re-evaluation
(in years)
Age at onset
(years)
Disease course Ataxia Dysmetria Speech IQ School Behaviour
CBCL T scores
3 1.5 Monophasic No No Normal n.t. y
*3.4 1.9 Monophasic No No Normal >85 y
5 1.0 >14 months rl Mild Mild Dysarthria <75 Special school 64
5.1 1.9 >14 months rl Minimal Minimal Dysarthria <75 Special school 61
**7 1.9 rl Minimal Minimal Normal <75 Special class 62
7 1.4 rl Minimal Minimal Normal 75–85 Special school 73
7.9 2.0 Monophasic No No Slurred >85 Special class 62
11.5 1.2 rl No No Normal, x >85 Regular 39
12 1.1 rl No Minimal Slurred >85 Regular 63
17.7 0.8 >24 months rl Minimal No Dysarthria <50 Special school 60
*neuroblastoma associated, ** ganglioneuroma associated
Disease course: monophasic: symptom control within 5 months, no relapses; rl: multiple relapses; >14, 24 months, respectively: no remission of
opsoclonus and myoclonus during that time on various medications.
n.t.: not tested
x: speech therapy earlier.
Special school: school for learning-disabled children, special class: class with fewer pupils but regular academic goals.
Behaviour: y: CBCL not applicable due to young age, but no problem evident at interview.
Normative mean of CBCL T scores: 50, SD 10, >60: borderline, >70 clinically significant behavioural problem.
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[16]. This may be due to less extensive investigation or to
genetic factors. Only two of our patients had an associated
tumour of the neural crest. This corresponds to the ratio of
paraneoplastic and “idiopathic” OMS in European studies.
Tate et al. compared patients with paraneoplastic and
idiopathic OMS and did not find any difference in the age
of onset, course and neurological outcome [24].
Regarding the long-term outcome, persistent and dis-
abling ataxia, speech abnormalities, behavioural problems,
and learning disabilities have been described. Most studies
had patient numbers between 10–21, but the largest series
(by Tate et al. [24] and Pohl et al. [16]) had 105 and 54
patients, respectively. The longest follow-up in a single
report was 41 years [18]. Complete recovery was seen in
only 12%–38% of the children [15, 16].
No correlation between outcome and response to
therapy, or removal of the tumour [7, 13, 15, 16, 24], or
delay in treatment has been found [8, 13, 16]. The interval
between the onset of symptoms and initiation of treatment
was 10.9 weeks (median) in the study by Pohl et al. [16],
and ranged from 1 week to 30 months (median 4 months) in
the study by Mitchell et al. [13]. The interval between onset
and diagnosis was 6 weeks to 1 year in the study by Koh et
al. [8], 1–24 weeks (median 6 weeks) in the study by
Plantaz et al. [15], and an average of 3 months in the study
by Tate et al. [24]. In our group of patients diagnosis was
made much more rapidly and therapy was started immedi-
ately regardless of tumour evaluation (median interval,
3 weeks). In one patient in whom treatment was delayed for
12 weeks, there were more significant motor and cognitive
sequelae, and symptoms were difficult to control. The three
children who had a long-lasting and severe acute phase
with worsening of symptoms during infections or tapering
of steroid dose over 12–24 months demonstrated a worse
long-term outcome, especially in cognition and behaviour.
Mitchell at al. [12] reported a better outcome in children
with a monophasic course of the disease. In our group,
seven children had relapses later than 2 years after
diagnosis, with variable control by immunosupressant
medication, and their outcome varied considerably between
being able to attend regular school and having significant
cognitive and behavioural sequelae. The three patients with
a monophasic course had a good outcome; one had
behavioural and speech problems. There was an overall
tendency towards a better cognitive and behavioural
outcome with better symptom control.
In terms of ataxia, our patients demonstrated a better
outcome as compared with the cases in the literature [6, 8,
12–16]. As shown in Table 1, only one of our patients had
mild ataxia at follow-up; four were graded as minimal with
normal gait and no motor handicap in everyday life, but
they were not age appropriate in standing on one leg. In
some children, ataxia was prominent in the first 2–4 years,
but had improved impressively by school age. The better
motor outcome may be due to faster initiation of treatment,
but this remains speculative because of the small number of
patients.
The cognitive, behavioural and language problems and
attention deficit symptoms have been described as sequelae
of OMS. Papero et al. [14] reported T scores of more than
60 in 7/8 of the children in the CBCL; IQ ranged from 50–
87 and verbal fluency was disrupted in 12/13. In the study
by Pohl et al. [16], 32/54 patients had a learning disability
and 33/54 a speech abnormality. Hayward et al. [7] reported
speech problems in 7/11, CBCL T scores >60 in 4/11, and
IQ >1 SD below the mean in 5/11. Koh et al. [8] described
problems in development including language deficits and
inattention and behavioural problems in nine of ten.
Mitchell et al. [13] reported IQ or developmental indices
ranging from 44 to 94, with only 3/17 with an IQ in the
normal range, and behavioural problems such as mood
swings, tantrums, or opposition behaviour in 10/17; 4 /17
children had CBCL scores >63, and all children had
speech abnormalities. In their longitudinal study, 4/5
patients with a monophasic course were functioning in
the average range of IQ and behaviour and adaptive skills:
in the second assessment, 7/16 had scores >60 and 3 >63,
and behavioural problems were stable compared with the
previous examination. In the study by Tate et al., 40% of
parents reported expressive language impairment and
25% behavioural problems as the largest remaining
problem following OMS [24]. Cognitive, behavioural,
attention and, to a lesser extent, speech problems were
particularly prominent in our patients on long-term
follow-up and also led to significant school problems in
patients with normal IQs.
Problems in executive function (planning, verbal
fluency, and working memory), spatial cognition (visual
spatial organisation and memory), language and person-
ality changes have been described as the cerebellar
cognitive affective syndrome following lesions of the
cerebellum (ischaemic lesions and tumour resections) [11,
21, 23]. The immunologic process of OMS may lead to
changes in the cerebellum that are responsible for atrophy
and the behavioural and cognitive problems on long-term
follow-up.
Only two of our patients with a monophasic disease
course had no residual problems, but they were the
youngest, and therefore it may well be that subtle cognitive
and behavioural problems are not yet detectable.
Concerning treatment, we report a good response in
opsoclonus and myoclonus with persisting ataxia to cyclo-
sporin A in two patients who were steroid dependant and
who did not respond to IVIG; in one patient, a relapse was
treated successfully with CSA, given because the parents
were reluctant to start steroids again.
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